JP2015513310A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513310A5 JP2015513310A5 JP2014547360A JP2014547360A JP2015513310A5 JP 2015513310 A5 JP2015513310 A5 JP 2015513310A5 JP 2014547360 A JP2014547360 A JP 2014547360A JP 2014547360 A JP2014547360 A JP 2014547360A JP 2015513310 A5 JP2015513310 A5 JP 2015513310A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- day
- insulin
- compound
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 9
- 102000004877 Insulin Human genes 0.000 claims 8
- 108090001061 Insulin Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940125396 insulin Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 239000007897 gelcap Substances 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- 229940122254 Intermediate acting insulin Drugs 0.000 claims 2
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 2
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 2
- 229940100066 Long-acting insulin Drugs 0.000 claims 2
- 108010026951 Short-Acting Insulin Proteins 0.000 claims 2
- 229940123958 Short-acting insulin Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 1
- 0 *=C1N=CC(*c2ccccc2)=CN1 Chemical compound *=C1N=CC(*c2ccccc2)=CN1 0.000 description 1
- HJQILFPVRNHTIG-UHFFFAOYSA-N Cc1cccc(OC(C=N2)=CNC2=O)c1 Chemical compound Cc1cccc(OC(C=N2)=CNC2=O)c1 HJQILFPVRNHTIG-UHFFFAOYSA-N 0.000 description 1
- OQXKUNREZFZTMU-UHFFFAOYSA-N O=C1N=CC(Oc2cc(Cl)ccc2)=CN1 Chemical compound O=C1N=CC(Oc2cc(Cl)ccc2)=CN1 OQXKUNREZFZTMU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569496P | 2011-12-12 | 2011-12-12 | |
| US61/569,496 | 2011-12-12 | ||
| PCT/US2012/069072 WO2013090319A2 (en) | 2011-12-12 | 2012-12-12 | Treatment of type i and type ii diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513310A JP2015513310A (ja) | 2015-05-07 |
| JP2015513310A5 true JP2015513310A5 (enExample) | 2016-01-28 |
| JP6152387B2 JP6152387B2 (ja) | 2017-06-21 |
Family
ID=48613352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547360A Active JP6152387B2 (ja) | 2011-12-12 | 2012-12-12 | Ｉ型およびｉｉ型糖尿病の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150190396A1 (enExample) |
| EP (1) | EP2790704B1 (enExample) |
| JP (1) | JP6152387B2 (enExample) |
| KR (1) | KR102069395B1 (enExample) |
| CN (2) | CN107007608B (enExample) |
| AU (2) | AU2012352480A1 (enExample) |
| BR (1) | BR112014014289A2 (enExample) |
| CA (1) | CA2859156C (enExample) |
| IL (1) | IL233004B (enExample) |
| MX (1) | MX359171B (enExample) |
| RU (1) | RU2646475C2 (enExample) |
| SG (2) | SG10201604828QA (enExample) |
| WO (1) | WO2013090319A2 (enExample) |
| ZA (1) | ZA201404738B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10863264B2 (en) | 2017-01-23 | 2020-12-08 | David Sampson | Vibration inducing tactile apparatus |
| MX2020007006A (es) * | 2018-01-11 | 2022-10-03 | Bukwang Pharmaceutical Co Ltd | Metodo para preparar tolimidona en gran escala. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3922345A (en) | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20070025953A1 (en) * | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| KR101577554B1 (ko) * | 2005-08-22 | 2015-12-14 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한 방법 및 제제 |
| RU2316339C1 (ru) * | 2006-09-13 | 2008-02-10 | Общество С Ограниченной Ответственностью "Концерн О3" | Способ получения препарата инсулина для перорального применения |
| AU2008218765A1 (en) * | 2007-02-20 | 2008-08-28 | Melior Pharmaceuticals I, Inc. | Methods of identifying activators of lyn kinase |
| EP2180894A4 (en) | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | METHOD OF ACTIVATING IRS-1 AND ACT |
| DK2355829T3 (en) * | 2008-12-12 | 2015-02-16 | Poxel S A S | COMBINATION OF INSULIN WITH tetrazine AND ITS USE FOR THE TREATMENT OF DIABETES |
| WO2011150300A1 (en) * | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3609500B1 (en) * | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
-
2012
- 2012-12-12 MX MX2014006990A patent/MX359171B/es active IP Right Grant
- 2012-12-12 SG SG10201604828QA patent/SG10201604828QA/en unknown
- 2012-12-12 BR BR112014014289A patent/BR112014014289A2/pt not_active Application Discontinuation
- 2012-12-12 CN CN201610988112.1A patent/CN107007608B/zh active Active
- 2012-12-12 JP JP2014547360A patent/JP6152387B2/ja active Active
- 2012-12-12 KR KR1020147019062A patent/KR102069395B1/ko active Active
- 2012-12-12 RU RU2014128528A patent/RU2646475C2/ru active
- 2012-12-12 EP EP12857229.4A patent/EP2790704B1/en active Active
- 2012-12-12 AU AU2012352480A patent/AU2012352480A1/en not_active Abandoned
- 2012-12-12 WO PCT/US2012/069072 patent/WO2013090319A2/en not_active Ceased
- 2012-12-12 CN CN201280069531.5A patent/CN104271140B/zh active Active
- 2012-12-12 US US14/364,792 patent/US20150190396A1/en not_active Abandoned
- 2012-12-12 SG SG11201403207WA patent/SG11201403207WA/en unknown
- 2012-12-12 CA CA2859156A patent/CA2859156C/en active Active
-
2014
- 2014-06-08 IL IL233004A patent/IL233004B/en unknown
- 2014-06-26 ZA ZA2014/04738A patent/ZA201404738B/en unknown
-
2017
- 2017-07-07 AU AU2017204652A patent/AU2017204652B2/en active Active
-
2020
- 2020-01-08 US US16/737,200 patent/US20200215068A1/en active Pending